Gwo Xi Stem Cell Applied Technology , Ltd Profit Margin

As of the most recent data (June 2026), 6704.TWO shows a profit margin of -49.36%. That compares with -59.85% in the prior-year period — up 17.5% year over year. That is below the Healthcare sector average of 10.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6704.TWO's profit margin is now -49.36% (was -59.85%) — a 17.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Gwo Xi Stem Cell Applied Technology , Ltd is outperforming or lagging.

The Healthcare sector average profit margin is about 10.58%. Gwo Xi Stem Cell Applied Technology , Ltd is at -49.36%, which is lower that average. That is roughly 566.5% below the sector mean. Use the comparison chart on this page to see how 6704.TWO stacks up against individual peers as well.

That compares with -59.85% in the prior-year period — up 17.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Gwo Xi Stem Cell Applied Technology , Ltd with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Gwo Xi Stem Cell Applied Technology , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -49.36%) with ownership activity and broader fundamentals.